Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).
Cardiovascular disease is the leading cause of death in Fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3
Think Fabry, think renal involvement that may present early in life and could go undetected.
Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2
A podcast series designed by cardiologists, for cardiologists and other healthcare professionals.
The Building Care webinar series is designed to deepen your understanding of the critical role a patient-centered, multidisciplinary approach plays in managing Fabry disease.
Lyssna på experter inom kardiologi som delar med sig av sina kunskaper i podden KardiologKvarten
Du är på väg att lämna campus.sanofi/se Sanofi ansvarar inte för innehållet på denna externa webbplats.
Den här webbplatsen innhåller information som endast är riktad till sjukvårdspersonal. Vänligen bekräfta nedan för att ta del av information, filmer, podcast och övrigt material.